EXPOSÉ: DEA's Marijuana Licensing Scheme Exposed
MMJ BioPharma Cultivation's case reveals DEA contradiction blocking FDA approved cannabis medicine.
Newly uncovered DEA agreements confirm that the agency's own rules make it impossible for any company to legally produce pharmaceutical grade cannabis for FDA authorized clinical research.
A recently disclosed memorandum of understanding between the DEA and a registered marijuana cultivator has revealed the DEA fatal flaw at the heart of America's cannabis research policy.
This proves MMJ BioPharma Cultivation's case and exposes why legitimate science has been paralyzed for nearly a decade.
Author's summary: DEA's rules hinder cannabis research.
More News
- Brisbane priests share All Souls’ Day cultural significance - The Catholic Leader
- Vance says troops to be paid despite shutdown but warns of ‘limited pot of money’
- Selling Sunset's Sandra Vergara on If Keyed Chrishell's Assistant's Car
- Down 30% and Still Growing its Payout: 1 Canadian Stock I'd Snap Up
- DWTS' Alan Bersten, Elaine Hendrix Taking 'It Easy' After Her Hospitalization
- Thieves Snag Custom Range Rover Owned By Shaquille O'Neal - SlashGear
- Lacoste Debuts Rolex Paris Masters 2025 Collection - V Magazine
- Lorient 1-1 PSG: Parisians held but remain top of Ligue 1
- Landry's Explosive Quote That Signals Major Changes at LSU
- The children are starving; God is screaming – Baptist News Global